Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarkers and surrogate endpoints for drug development in propionic acidemia.

Molecular genetics and metabolism·2026
Same author

Current status in paediatric liver transplantation for inherited metabolic diseases.

Journal of pediatric gastroenterology and nutrition·2026
Same author

First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders.

Journal of inherited metabolic disease·2026
Same author

Neurological manifestations and genotype-phenotype correlations in <i>NDUFAF6</i>-associated mitochondrial disease.

Brain communications·2026
Same author

Diagnostic delay in inherited metabolic diseases: Insights from the U-IMD registry.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

The Role of Homocysteine in Pediatric MASLD: A Bipotential Biomarker of Cardiovascular Risk and Liver Fibrosis.

Life (Basel, Switzerland)·2026

Related Experiment Video

Updated: May 18, 2026

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools
05:27

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools

Published on: July 20, 2022

Pediatric reference intervals for muscle coenzyme Q(10).

Anna Pastore1, Gianna Di Giovamberardino, Sara Petrillo

  • 1Laboratory of Metabolomics and Proteomics, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy. anna.pastore@opbg.net

Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|October 2, 2012
PubMed
Summary

Coenzyme Q(10) deficiency in children can be identified by measuring muscle levels. Early detection of mild, intermediate, or severe CoQ(10) deficiency aids in timely supplementation, especially for neurodegenerative conditions.

More Related Videos

Quantification of Coenzyme A in Cells and Tissues
08:51

Quantification of Coenzyme A in Cells and Tissues

Published on: September 27, 2019

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

Related Experiment Videos

Last Updated: May 18, 2026

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools
05:27

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools

Published on: July 20, 2022

Quantification of Coenzyme A in Cells and Tissues
08:51

Quantification of Coenzyme A in Cells and Tissues

Published on: September 27, 2019

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

Area of Science:

  • Biochemistry
  • Pediatrics
  • Neuroscience

Background:

  • Coenzyme Q(10) (CoQ(10)) exists as ubiquinol (CoQ(10)H(2)) and ubiquinone (CoQ(10)).
  • CoQ(10) is a vital cofactor for mitochondrial ATP production via oxidative phosphorylation.

Purpose of the Study:

  • To establish reference ranges for CoQ(10) levels in pediatric skeletal muscle.
  • To define thresholds for severe, intermediate, and mild CoQ(10) deficiency.

Main Methods:

  • High-performance liquid chromatography (HPLC) with electrochemical detection was used.
  • CoQ(10) levels (total, reduced, oxidized) were quantified in skeletal muscle tissue from 148 children.

Main Results:

  • Three distinct CoQ(10) level thresholds were established for pediatric skeletal muscle.
  • Severe deficiency: 0.82–4.88 μmol/g tissue.
  • Intermediate deficiency: 5.40–9.80 μmol/g tissue.
  • Mild deficiency: 10.21–19.10 μmol/g tissue.

Conclusions:

  • Early identification of CoQ(10) deficiency is crucial in children.
  • Supplementation with CoQ(10) may benefit children with primary defects or neurodegenerative disorders.
  • Establishing deficiency levels facilitates timely therapeutic intervention.